Hair Restore D Scalp Solution (Dutasteride) (60 mL)

It is commonly used for androgenetic alopecia (male or female pattern baldness) and other scalp-related conditions that lead to hair shedding.
The solution typically contains Minoxidil and Finasteride, two active ingredients known to stimulate hair growth and prevent further loss. Some formulations may also include DHT blockers, caffeine, ketoconazole, or biotin, depending on the brand.

1. Minoxidil
⦁ Prolongs Anagen Phase: Extends the growth phase of the hair cycle, leading to thicker and longer hair strands.
⦁ Follicle Stimulation: Reactivates shrunken hair follicles, encouraging new hair growth.
2. Finasteride (Topical)
⦁ DHT Blocker: Inhibits the conversion of testosterone to dihydrotestosterone (DHT), a hormone that shrinks hair follicles in androgenetic alopecia.
⦁ Reduces Hair Follicle Miniaturization: Helps prevent further thinning and promotes regrowth by maintaining follicle size.
3. Other Ingredients (if included)
⦁ Caffeine: May stimulate hair shaft elongation and counteract DHT.
⦁ Ketoconazole: An antifungal agent that reduces scalp inflammation and may support hair growth.

Contraindications
⦁ Hypersensitivity to any ingredient in the formulation.
⦁ Scalp infections, open wounds, or skin irritation in the area of application.
⦁ Use in children under 18 unless prescribed by a doctor.
Precautions
⦁ Avoid contact with eyes, mouth, or broken skin.
⦁ Wash hands after application.
⦁ Use only on dry scalp and as directed.
⦁ Do not use with other topical scalp treatments unless advised by a healthcare provider.
⦁ Avoid use if there is a history of cardiovascular disease, especially when using Minoxidil, due to potential systemic absorption.
Keep out of reach of children.

Common Side Effects
⦁ Scalp irritation or dryness
⦁ Itching or flaking at the application site
⦁ Temporary hair shedding (initial phase)
Less Common but Possible
⦁ Unwanted facial or body hair (if the solution drips onto other areas)
⦁ Headache or dizziness
⦁ Local allergic reaction (redness, swelling)
Rare but Serious
⦁ Chest pain, rapid heartbeat (due to systemic absorption of Minoxidil)
⦁ Severe skin reaction or rash
⦁ Swelling of face or limbs (may indicate allergic response)

Pregnancy
⦁ Not recommended during pregnancy.
⦁ Finasteride is classified as Pregnancy Category X and should be avoided, as it can cause harm to a developing fetus (especially male).
⦁ Topical Minoxidil is generally not advised due to limited safety data.
Breastfeeding
⦁ Caution is advised.
⦁ Consult a healthcare provider before use during lactation.

Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. National Library of Medicine. (n.d.). Exploratory Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia. Clinical Trials.gov. https://clinicaltrials.gov/study/NCT05599243– LinkOpens in New Tab
2. Shanshanwal, S. J., & Dhurat, R. S. (2017). Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian journal of dermatology, venereology and leprology, 83(1), 47–54. https://doi.org/10.4103/0378-6323.188652– LinkOpens in New Tab
3. Roehrborn C, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Uro
4. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. Retrieved June 9, 2011. Available on the World Wide Web at: http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm– LinkOpens in New Tab
5. McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association guideline: management of benign prostatic hyperplasia (BPH). Linthicum, MD: American Urological Association; 2010. 1-62; Appendix 278-85. Retrieved on February 4, 2020. Available on the Worldwide Web at https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014).– LinkOpens in New Tab
6. Dimitropoulos K, Gravas S. Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Ther Adv Urol 2016;8:19-28.
7. Harcha WG, Martinez JB, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol 2014;70:489-98.
8. Avodart (dutasteride soft gelatin capsules) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2020 Jan.
9. Amory JK, Wang C, Swerdloff RS, et al. The effect of 5-alpha-reductaxe inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrin Metab 2007;92(5):1659-65
10. Nada, E.A., Sharkawy, R.E., Maged, W.M., & Elmagd, M.A. (2018). Topical dutasteride with microneedling in treatment of male androgenetic alopecia. Southern Medical Journal, 22, 387-400.https://smj.journals.ekb.eg/article_42083_24b61cbba4be9982db23c318414034c0.pdf